Slide 1: Thyrocare – Investor Presentation Q3 Results cover letter
Thyrocare’ Think Thyroid. Think Thyrocare. February 05, 2018. The National Stock Exchange of India Limited The Bombay Stock Exchange Ltd Exchange Plaza Phiroze Jeejeeboy Towers Bandra Kurla Complex, Dalal Street, Bandra (E), Mumbai - 400 051 Mumbai- 400 001 Dear Sir/Madam, Sub: Investor Presentation
Slide 2: Thyrocare Technologies Limited Q3-FY18 Presentation
Thyrocare Technologies Limited Q3-FY18 Presentation
Slide 3: Disclaimer
Disclaimer • This presentation is for information purposes only and it contains general background information about the Company’s activities. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements on the basis of any subsequent development, informat
Slide 4: Transition to IndAS (Indian Accounting Standards)
Transition to IndAS (Indian Accounting Standards) Key IndAS Adjustments: [Rs. in million] Nine months ended Quarter ended 31 December 2016 31 December 2016 • Re-imbursement of advertisement expenses by shareholders – Non reciprocal contributions received from the shareholders are considered as capit
Slide 5: Consolidated Financials
Consolidated Financials Thyrocare Technologies Limited [Consolidated] Thyrocare Technologies Limited [Consolidated] P&L Statement (INR mn, except per share data) Balance Sheet (INR mn) Particulars Year to Date YoY Growth 3 months ended YoY Growth Particulars 31 Dec 17 31 Dec 16 31 Dec 17 31 Dec 16 3
Slide 6: Thyrocare Standalone
Thyrocare Standalone Thyrocare’ ‘Think Thyroid. Think Thyrocare
Slide 7: Standalone Financials
Standalone Financials Thyrocare Technologies Limited (Standalone) Thyrocare Technologies Limited (Standalone) P&L Statement (INR mn, except per share data) Balance Sheet (INR mn) Particulars Year to Date YoY Growth 3 months ended YoY Growth Particulars 31 Dec 17 31 Dec 16 31 Dec 17 31 Dec 16 31 Dec
Slide 8: YTD Performance Highlights - Thyrocare
YTD Performance Highlights - Thyrocare • Nine months and Quarterly standalone net profit of INR 705.67 million and INR 217.51 million, up 32% and 29%, respectively (Normalized for the adjustment on account of reimbursement towards advertisement from the shareholder and adjustment of revenue/ cost of
Slide 9: Key Financial Trends - Thyrocare
Key Financial Trends - Thyrocare Revenue (INR mn) EBITDA (INR mn) 357.6 821.4 817.9 823.6 338.8 336.7 778.4 313.0 734.0 298.7 645.1 656.9 261.3 259.7 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 FY17 FY18 FY17 FY18 44% 43% EBITDA Margin(%) 41% 41% 41% 40% 38% Q1 - FY17 Q2 - FY17 Q3 - FY17 Q4 - FY17 Q1 - FY18 Q2 - FY18 Q
Slide 10: Key Operating Metrics – Business Lines
Key Operating Metrics – Business Lines Revenue Breakup (INR mn) Volume Breakup (‘000 Samples) Q3-FY18 129 210 14 370 Q3-FY18 99.9 328.0 185.9 3,259.4 Q2-FY18 167 238 17 341 Q2-FY18 126.2 374.4 219.5 3,362.3 Q1-FY18 188 227 19 328 Q1-FY18 146.9 357.0 237.5 3,276.4 Q4-FY17 185 243 20 313 Q4-FY17 149.7
Slide 11: Key Operating Metrics – Regional Breakup
Key Operating Metrics – Regional Breakup Value Breakup (INR mn) Volume Breakup (mn Samples) Q3-FY18 131 183 266 125 19 Q3-FY18 0.7 1.2 0.8 0.9 0.2 Q2-FY18 226 197 205 132 3 Q2-FY18 1.0 1.2 0.9 0.9 Q1-FY18 206 199 221 132 4 Q1-FY18 1.0 1.2 0.9 0.9 Q4-FY17 188 200 237 131 4 Q4-FY17 0.9 1.2 1.0 0.9 Q3-
Slide 12: Operating Data
Operating Data Thyrocare Technologies Limited (Rs. in million, except per share data) Particulars Year to Date YoY Growth 3 months ended YoY Growth 31 Dec 2017 31 Dec 2016 31 Dec 2017 31 Dec 2016 B2B revenue (in million) 1,714.86 1,450.41 18% 581.18 454.62 28% B2C revenue (in million) 534.27 421.61
Slide 13: Nueclear Standalone
Nueclear Standalone Nue@clear
Slide 14: Standalone Financials - Nueclear
Standalone Financials - Nueclear Nueclear Healthcare Limited (Standalone) Nueclear Healthcare Limited (Standalone) P&L Statement (INR mn, except per share data) Balance Sheet (INR mn) Particulars Year to Date YoY Growth 3 months ended YoY Growth Particulars 31 Dec 17 31 Dec 16 31 Dec 17 31 Dec 16 31
Slide 15: YTD Performance Highlights - Nueclear
YTD Performance Highlights - Nueclear • YTD and 3Q-FY18A standalone EBITDA of INR 33.7 million and INR 14.0 million respectively. • YTD and 3Q-FY18A standalone revenue from operations of INR 179.0 million (31% growth) and INR 60.3 million, up 29% (Normalized for the adjustment of revenue/ cost of im
Slide 16: Key Financial Trends - Nueclear
Key Financial Trends - Nueclear Revenue (INR mn) EBITDA (INR mn) 62.5 60.3 15.4 56.2 14.0 47.4 46.8 47.6 42.3 4.3 4.0 1.8 1.8 0.3 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 FY17 FY18 FY17 FY18 EBITDA Margin 25% 24% 10% 7% 4% 4% 1% Q1-FY17 Q2-FY17 Q3-FY17 Q4-FY17 Q1-FY18 Q2-FY18 Q3-FY18
Slide 17: Centerwise Scan Volumes
Centerwise Scan Volumes Centerwise Scan Volumes 100% 49 158 320 199 304 373 440 356 460 538 529 580 440 90% 471 436 611 579 689 548 80% 659 725 70% 738 808 2,014 1,863 1,724 1,879 2,101 2,339 60% 1,972 1,766 2,090 50% 1,839 1,646 40% 30% 20% 1,662 1,723 1,684 1,582 1,731 1,889 1,717 1,741 1,967 1,83
Slide 18: Centerwise Scan Revenues
Centerwise Scan Revenues Centerwise Scan Revenues (INR mn) 100% 0.8 1.0 2.8 3.2 4.8 3.3 4.1 4.5 4.8 5.2 5.2 5.7 3.2 90% 5.6 7.0 3.2 5.7 8.2 80% 6.6 6.4 7.1 70% 7.6 16.4 15.3 14.4 8.3 15.7 17.2 19.1 60% 16.0 14.8 50% 18.4 18.6 16.2 40% 30% 14.5 15.2 15.8 15.5 20% 15.9 17.4 15.6 15.9 18.2 18.3 17.3 10
Slide 19: Thank You
Thank You O Think Thyroid. Think Thyrocare. Nuclear NATIONWIDE NETWORKED